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Ewing￿s sarcoma is a rare form of primitive, highly cellular malig-
nant round-cell tumour of bone and soft tissue originally described
by Ewing (1921). It is the second most common primary malig-
nant tumour of bone diagnosed in childhood after osteosarcoma
(Glass and Fraumeni, 1970), and accounts for about 10% of all
primary malignant bone tumours (Larsson and Lorentzon, 1974;
Price and Jeffree, 1977). The important prognostic factors at the
time of diagnosis include the presence or absence of metastases
(Cangir et al, 1990; Huvos, 1991) and, possibly, the volume of
tumour at diagnosis (Mendenhall et al, 1983; Sauer et al, 1987).
There is currently no histological grading system to indicate
biological aggression of the tumour in patients with localized
Ewing￿s sarcoma at diagnosis because of the highly primitive
nature of this tumour. Identification of factors which may indicate
the biological aggression of tumours in different patients with
primary Ewing￿s sarcoma of bone will be beneficial for the treat-
ment of patients with localized disease at the time of diagnosis.
The wild-type p53tumour-suppressor gene is located on the
short arm of chromosome 17 in the region of 17p13 and encodes
for a 53-kDa nuclear phosphoprotein with sequence-specific
DNA-binding properties. The p53gene product is a transcription
factor which has two main functions: (i) it acts to maintain genetic
stability and induce cell cycle arrest by inhibiting cells from
entering the S-phase of the cell cycle and (ii) to induce apoptosis in
the presence of genotoxicity (Lane, 1993). The wild-type p53
protein has a short half-life of 20—30min in most cells and is
considered to be undetectable because of its rapid elimination
(Levine, 1992).
Mutation of the p53gene is the most common genetic abnor-
mality associated with malignancy (Greenblatt et al, 1994). The
product of mutant p53gene is characterized by conformational
change of the protein with resultant prolonged half-life and
stability and a loss of the ability to arrest cell cycle or induce apop-
tosis. It may further inhibit the activity of the wild-type p53
protein. Numerous studies have shown a close positive correlation
between mutations of p53gene and overexpression of p53 protein
(Bartek et al, 1990; Davidoff et al, 1991; Esrig et al, 1993). This
close correlation is maintained in paraffin-embedded formalin-
fixed archived tissues with most antibodies giving similar results
(Bass et al, 1994), but it is unclear whether any differences exist
between antigen retrieval in archived pufffin-embedded formalin-
fixed tissues and fresh tumour tissues.
The exact role of the p53tumour-suppressor gene in the primary
development of malignancies is still unclear. Mutations of the p53
gene have been implicated in a variety of carcinomas and
sarcomas, and there is increasing evidence in the literature that
these abnormalities are associated with high histological grade and
adverse prognosis (Isola et al, 1992; Hsu et al, 1993; Toguchida et
al, 1993; Cordon-Cardo et al, 1994; Mangham et al, 1995). We
have used immunohistochemisty to investigate abnormalities of
p53gene protein in patients with primary Ewing￿s sarcoma with a
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Northfield, Birmingham B31 2AP, UKview to determining its significance in the diagnosis and prognosis
of this disease.
MATERIALS AND METHODS
Immunohistochemistry for p53 protein was performed on 4-mm
sections of archived formalin-fixed and paraffin-embedded
pretreatment biopsy specimens of 52 patients (63%) out of a total
of 83 patients, who had diagnostic biopsy and treatment of primary
Ewing￿s sarcoma of bone at our centre between 1983 and 1993.
Thirty-one patients were excluded from the study because the
original biopsy tissues could not be traced in 18 patients, sufficient
tissues were not available for examination in 11, and two were
reclassified as small-cell osteosarcoma (one) and chronic
osteomyelitis (one).
All the tumours studied were composed of sheets of small round
cells with pale, poorly delineated cytoplasm rich in glycogen and
with single monotonous round to oval nuclei with frequent mitosis
and inconspicuous nucleoli. Variable amounts of necrosis and
haemorrhage were often present. There was negative immuno-
staining for leucocyte common antigen (CD45), desmin, S-100
and cytokeratin. There was positive staining for vimentin and
MIC-2GP (CD99).
The avidin—biotin complex method for immunostaining was
used for each section, with monoclonal antibody PAb 1801
(Novocastra, UK) at a predetermined optimal dilution of 1:50 and
polyclonal antibody NCL-CM I diluted 1:500 (Novocastra).
Antigen retrieval was performed by microwave heating in citrate
buffer, pH 6.0 (Cattoretti et al, 1992). A gastric carcinoma known
to express p53 protein was used as positive control, and thyroglob-
ulin and ret-40 were used as negative controls for the polyclonal
and monoclonal antibodies respectively. Eighteen patients had two
or three different blocks of biopsy tissues and 34 patients each had
only one block of biopsy tissues available for immunohistochem-
ical staining. Consecutive areas of the sections were examined
independently by two observers who were blind to the clinical
details of the patients. Overexpression was recorded when positive
staining was present in more than 10% of the cells. The presence
or absence of overexpression was, in all instances, distinct in that
more than half of the cells in tumours overexpressing p53 stained
positively and virtually no cells in the p53-negative cases demon-
strated immunostaining. No borderline cases were identified.
The clinical records of the patients were retrieved from the data-
base. All the patients had full staging studies consisting of routine
haematological and serum biochemical parameters, whole body
bone scintigraphy, and computerized tomography (CT) scans of
the chest and local tumour. More recently, magnetic resonance
imaging scans have replaced CT scans of the tumour site. All the
patients received combination chemotherapy consisting of
vincristine, doxorubicin, ifosfamide, cyclophosphamide, etopo-
side and actinomycin D. Treatment of the local tumour was
surgery and/or radiotherapy. Full follow-up data were available for
all patients.
The disease-free survival and overall survival were analysed
according to the Kaplan—Meier method (Kaplan and Meier, 1958)
only in patients without metastases at diagnosis. Disease-free
survival was defined from the time of diagnosis to either the date of
review or recurrence at local or distant sites. The overall survival
was defined from the time of diagnosis to the date of review or date
of death. Treatment-related death was counted as an event. The
analyses for disease-free and overall survival were confined only to
those patients without metastases at the time of diagnosis.
Statistical comparisons of survival curves were performed by the
Mantel—Cox log-rank test (Mantel, 1966). Cox proportional
hazards regression model (Cox, 1972) was used to study the joint
influence of factors which might alter survival time. Fisher￿s exact
test was used to evaluate the relationship between p53 and tumour
stage at diagnosis and response to chemotherapy; relative risk (RR)
and 95% confidence intervals (CI) were calculated. P value < 0.05
was considered statistically significant.
RESULTS
Fifty-two patients with Ewing￿s sarcoma of bone were studied.
The mean age at diagnosis was 17 years (range 6—36 years). There
were 30 males and 22 females. The tumours were located in bones
of the extremities in 35 patients, pelvis in 13 patients, scapula in
three patients and clavicle in one patient. This is similar to known
distribution of Ewing￿s sarcoma (Huvos, 1991). Patients with
pelvic, scapular and clavicular tumours were classified as having
central tumours. Seven patients had metastases at diagnosis. The
minimum follow-up was 30 months from the time of diagnosis.
p53 overexpression was demonstrated in seven patients (14%).
There were consistent results in patients from whom multiple
1186 A Abudu et al
British Journal of Cancer (1999) 79(7/8), 1185–1189 © Cancer Research Campaign 1999
0 24 48 60 84 108 120 96 72 36 12 132 144 156
Time (months)
0.2
0.0
1.0
0.4
0.8
0.6
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
Normal p53 status
p53 overexpression
0 24 48 60 84 108 120 96 72 36 12 132 144 156
Time (months)
0.2
0.0
1.0
0.4
0.8
0.6
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
Normal p53 status
p53 overexpression
Figure 1 Disease-free survival according to p53 protein status
Figure 2 Overall survival according to p53 protein statusblocks of biopsy tissues were studied and between the two anti-
bodies used. The relationship of p53 expression to the site of
tumour, stage of tumour at diagnosis and the amount of necrosis
within the tumour after preoperative chemotherapy were studied in
all the patients. The disease-free survival and overall survival were
studied only in those patients who did not have metastases at the
time of diagnosis.
p53 overexpression and site of tumours
There was no significant relationship between overexpression of
p53 and location of tumours (P > 0.9). The site of the tumour was
central in two patients and in the extremity bones in five patients,
in those with p53 overexpression. In the patients with no p53 over-
expression, the tumours were located in the central bones in 15
patients and in the extremity bones in 30 patients.
Relationship between p53 overexpression, tumour
stage at diagnosis and post-chemotherapy necrosis
Metastatic disease was present at diagnosis in two patients (29%)
out of the seven patients in whom there was overexpression of p53
protein. Of the 45 patients who did not overexpress p53 protein,
five patients (11%) had metastases at diagnosis.
The amount of necrosis within the excised tumour had been esti-
mated from numerous samples taken from different parts of the
excised tumours after a course of preoperative chemotherapy.
Thirty-seven patients who did not have radiotherapy before exci-
sion of tumours were considered suitable for evaluation of the
influence of overexpression of p53 protein on tumour necrosis.
The amount of necrosis in the tumours was recorded as percent-
ages of the whole tumour. In this study, patients were classified as
￿good responders￿ when there was 90% or more necrosis and ￿poor
responders￿ when necrosis was less than 90%. Five patients (14%)
out of the 37 patients studied demonstrated p53 overexpression. Of
the five patients who expressed p53, only one patient (20%) had a
good response to chemotherapy compared with 15 patients (47%)
out of the 32 patients who did not express p53.
Although it appeared that there was a trend for Ewing￿s sarcoma
overexpressing p53 protein to have more advanced disease at diag-
nosis and poorer response to chemotherapy, this observed differ-
ence did not reach statistical significance (P = 0.4, RR 2.6, 95% CI
1.2 — 5.9 for tumour stage; P = 0.3, RR 1.5, 95% CI 1.8—4.0 for
necrosis).
p53 over expression and patients’ survival
Survival analysis was performed in 45 patients who did not have
metastases at the time of diagnosis. These included five patients
with overexpression of p53 protein, and all these had surgical exci-
sion and endoprosthetic reconstruction of tumours located in the
extremity bones in four patients and pelvic bone in one patient.
Overexpression of p53 protein was not demonstrated in 40
patients, 13 of these had central tumours and 27 had tumours of the
extremity skeleton. The treatment of the local tumour in the latter
group was surgical excision of expendable bones in ten patients,
excision and endoprosthetic reconstruction in 21 and conventional
radiotherapy in nine patients. The disease-free survival and overall
survival of patients with p53 overexpression was significantly
worse than those without p53 overexpression. The disease-free
survival for patients with overexpression of p53 protein was 20%
at 2 years and 5 years compared with 72% 2-year disease-free
survival and 66% 5-year disease-free survival in the patients who
did not overexpress p53 protein (P = 0.02), as shown in Figure 1.
The overall survival at 2 years and 5 years for patients with p53
overexpression was 20% compared with 85% 2-year survival and
71% 5-year survival for the patients who did not express p53
protein (P = 0.01), as shown in Figure 2.
The poorer overall survival for patients with expression of p53
protein was independent of tumour necrosis, site of tumour and the
method of treatment of the local tumour (i.e. surgery and/or radio-
therapy), with P-values of <0.05 according to the Cox proportional
hazard model (Table 1). The poorer disease-free survival was
also independent of site of tumour and method of treatment
(Table 2).
DISCUSSION
Expression of p53 protein is a rare event in primary Ewing￿s
sarcoma of bone. Only 14% of patients with Ewing￿s sarcoma of
bone in this study demonstrated abnormalities of p53 protein
expression. This figure is similar to those obtained by other
authors (Kovar et al, 1993; Mangham et al, 1995). We have delib-
erately studied pretreatment biopsy tissues because the effect of
chemotherapy or radiotherapy on p53 detection is uncertain. In
those patients from whom multiple specimens of biopsy tissues
were studied, the results in all the specimens were similar for each
patient, demonstrating that the p53 protein expression is diffuse
within the tumour.
There was a trend for patients with Ewing￿s sarcoma who
expressed p53 protein to have more advanced stage disease at
p53 overexpression in Ewing’s sarcoma 1187
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Table 1 Relative risk (RR) of death, confidence intervals (CI) and P-values
estimated by Cox proportional hazard model analysis of the interaction
between site of primary tumour, tumour necrosis, method of treatment of
local disease and p53 overexpression
RR CI P-value
p53 3.6 1.9–18.4 0.01
Method of local treatment 1.2 0.72–2.1 0.38
Necrosis 1.8 0.90–2.5 0.05
Site of tumour 1.0 0.72–3.9 0.8
Table 2 Relative risk (RR) of relapse of disease, confidence intervals (CI)
and P-values estimated by Cox proportional hazard model analysis of the
interaction between site of primary tumour, tumour necrosis, method of
treatment of local disease and p53 overexpression
RR CI P-value
p53 2.8 1.17–16.6 0.02
Method of local treatment 1.1 0.93–1.8 0.30
Necrosis 1.5 0.83–2.7 0.07
Site of tumour 1.0 0.45–2.2 0.43diagnosis and poorer response to chemotherapy than with patients
who showed no expression of p53 protein and in whom the p53
gene was presumably normal. Of the patient who demonstrated
p53 expression, 29% had disseminated metastases at diagnosis
compared with 11% of those without p53 expression. Only 20% of
the patients with expression of p53 protein had a good response to
chemotherapy, whereas 47% of patients who did not express p53
protein had a good response to preoperative chemotherapy.
However, these differences were not statistically significant for the
small number of patients in this study.
The differences in the disease-free survival and overall survival
of patients with manifest expression of p53 protein and those
without are particularly striking. Only 20% of patients who
expressed p53 protein remained free of disease at 5 years
compared with 66% of patients who did not express p53 protein.
The overall survival of patients who expressed p53 protein was
20% at 2 years and 5 years compared with 85% and 71% at 2 years
and 5 years, respectively, in those without expression of p53
protein. These differences are statistically significant, and are
independent of location of the tumour, post-chemotherapy
necrosis and type of treatment used for the local tumour.
Our results are similar to those obtained by Mangham et al
(1995), who in a study of 38 patients with Ewing￿s sarcoma treated
at the Massachusetts General Hospital, Boston, USA, found three
patients (8%) to express p53 protein. All the patients who
expressed p53 protein died by 15 months after diagnosis compared
with 50% 5-year survival for patients who did not express p53
protein. This is the only other study of the prognostic relevance of
p53 protein expression in Ewing￿s sarcoma.
The rarity of abnormalities of the p53 gene and its protein in
Ewing￿s sarcoma of bone suggests that this gene probably plays no
significant role in the primary pathogenesis of Ewing￿s sarcoma of
bone. However, it appears that abnormalities of the p53 gene
resulting in expression of the p53 protein occur later in the
progression of Ewing￿s sarcoma, and may indicate the assumption
of a more aggressive course.
At the present time, there is no histological grading system to
indicate the biological behaviour of Ewing￿s sarcoma in different
patients. There is an urgent need for identification of biological
factors which may allow stratification of patients with localized
Ewing￿s sarcoma of bone according to biological aggression of the
tumour before commencement of treatment or early in the course of
treatment. The present clinical prognostic factors only allow retro-
spective identification of those patients with poor prognosis during
treatment. Routine examination of pretreatment biopsy tissues of
Ewing￿s sarcoma for expression of p53 protein may allow identifi-
cation of those tumours that are likely to have a more aggressive
course resulting in poor prognosis on the current treatment
regimen. This will be very useful in patients who present with
localized Ewing￿s sarcoma, in whom there is presently no definite
indicator of prognosis before commencement of treatment.
CONCLUSION
Expression of p53 protein due to mutations of the p53 gene is rare
in patients with Ewing￿s sarcoma of bone. However, patients with
Ewing￿s sarcoma who express p53 protein appear to present with
more advanced disease and have poorer response to chemotherapy
than patients who do not have expression of the p53 protein. The
disease-free survival and overall survival of patients with Ewing￿s
sarcoma with expression of p53 protein are significantly worse
than those without p53 protein expression. Although the number
of patients in this series is small, the data presented provide strong
evidence that immunodetectable p53 expression is associated with
poor prognosis in patients with Ewing￿s sarcoma of bone which
needs to be investigated with a larger number of patients.
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